Cyclacel Pharmaceuticals (CYCC) Revenue & Revenue Breakdown
Cyclacel Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$420.00K
Latest Revenue (Q)
$4.00
Cyclacel Pharmaceuticals Revenue by Period
Cyclacel Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $420.00K | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | -100.00% |
| 2018-12-31 | $150.00K | 100.00% |
| 2017-12-31 | - | -100.00% |
| 2016-12-31 | $843.00K | -56.64% |
| 2015-12-31 | $1.94M | 12.11% |
| 2014-12-31 | $1.73M | 59.96% |
| 2013-12-31 | $1.08M | 1471.01% |
| 2012-12-31 | $69.00K | -90.13% |
| 2011-12-31 | $699.00K | 1.90% |
| 2010-12-31 | $686.00K | -24.70% |
| 2009-12-31 | $911.00K | 3.88% |
| 2008-12-31 | $877.00K | 579.84% |
| 2007-12-31 | $129.00K | -66.67% |
| 2006-12-31 | $387.00K | -52.40% |
| 2005-12-31 | $813.00K | 1211.29% |
| 2004-12-31 | $62.00K | -63.53% |
| 2003-12-31 | $170.00K | 100.00% |
| 2002-12-31 | - | -100.00% |
| 2001-12-31 | $30.00K | -69.39% |
| 2000-12-31 | $98.00K | - |
Cyclacel Pharmaceuticals generated $420.00K in revenue during NA 2023, up 100.00% compared to the previous quarter, and up 280.00% compared to the same period a year ago.
Cyclacel Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $4.00 | -99.99% |
| 2024-03-31 | $29.00K | -6.45% |
| 2023-12-31 | $31.00K | 93.75% |
| 2023-09-30 | $16.00K | -95.71% |
| 2023-06-30 | $373.00K | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | -100.00% |
| 2018-12-31 | $150.00K | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | -100.00% |
| 2016-12-31 | $277.00K | 35.12% |
| 2016-09-30 | $205.00K | -7.66% |
| 2016-06-30 | $222.00K | 59.71% |
| 2016-03-31 | $139.00K | -66.98% |
| 2015-12-31 | $421.00K | -41.12% |
| 2015-09-30 | $715.00K | 141.55% |
| 2015-06-30 | $296.00K | -42.19% |
| 2015-03-31 | $512.00K | 107.29% |
| 2014-12-31 | $247.00K | -66.39% |
| 2014-09-30 | $735.00K | 106.46% |
| 2014-06-30 | $356.00K | -10.10% |
| 2014-03-31 | $396.00K | 32.44% |
| 2013-12-31 | $299.00K | -3.24% |
| 2013-09-30 | $309.00K | 17.05% |
| 2013-06-30 | $264.00K | 24.53% |
| 2013-03-31 | $212.00K | 4140.00% |
| 2012-12-31 | $5.00K | -86.84% |
| 2012-09-30 | $38.00K | -73.97% |
| 2012-06-30 | $146.00K | -9.32% |
| 2012-03-31 | $161.00K | -8.00% |
| 2011-12-31 | $175.00K | 6.71% |
| 2011-09-30 | $164.00K | -2.38% |
| 2011-06-30 | $168.00K | -12.50% |
| 2011-03-31 | $192.00K | 39.13% |
| 2010-12-31 | $138.00K | -13.21% |
| 2010-09-30 | $159.00K | 33.61% |
| 2010-06-30 | $119.00K | -56.09% |
| 2010-03-31 | $271.00K | 44.92% |
| 2009-12-31 | $187.00K | -18.70% |
| 2009-09-30 | $230.00K | -13.53% |
| 2009-06-30 | $266.00K | 16.67% |
| 2009-03-31 | $228.00K | -9.16% |
| 2008-12-31 | $251.00K | -6.69% |
| 2008-09-30 | $269.00K | 49.44% |
| 2008-06-30 | $180.00K | 1.69% |
| 2008-03-31 | $177.00K | 1375.00% |
| 2007-12-31 | $12.00K | - |
Cyclacel Pharmaceuticals generated $4.00 in revenue during Q2 2024, up -99.99% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Cyclacel Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| OVID | Ovid Therapeutics | $391.69M | $169.00K |
| CTMX | CytomX Therapeutics | $101.21M | $25.11M |
| SPRO | Spero Therapeutics | $96.73M | $10.20M |
| IKNA | Ikena Oncology | $9.16M | - |
| PULM | Pulmatrix | $7.30M | $1.55M |
| ASMB | Assembly Biosciences | $7.16M | $5.79M |
| CBIO | Gyre Therapeutics | $794.00K | - |
| CYCC | Cyclacel Pharmaceuticals | $420.00K | $4.00 |
| RZLT | Rezolute | - | - |
| CNTB | Connect Biopharma | - | - |
| MBRX | Moleculin Biotech | - | - |
| NXTC | NextCure | - | - |
| AKTX | Akari Therapeutics | - | - |
| CYT | Cyteir Therapeutics | - | - |
| ELYM | Eliem Therapeutics | - | - |
| NLTX | Neurogene | - | - |
| TPST | Tempest Therapeutics | - | - |
| PTIX | Protagenic Therapeutics | - | - |
| EWTX | Edgewise Therapeutics | - | - |
CYCC Revenue FAQ
What is Cyclacel Pharmaceuticals’s yearly revenue?
Cyclacel Pharmaceuticals's yearly revenue for 2023 was $420K, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. CYCC's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is Cyclacel Pharmaceuticals’s quarterly revenue?
Cyclacel Pharmaceuticals's quarterly revenue for Q2 2024 was $4, a -99.99% decrease from the previous quarter (Q1 2024), and a -100.00% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $29K, a -6.45% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). CYCC's quarterly revenue for Q4 2023 was $31K, a 93.75% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022).
What is Cyclacel Pharmaceuticals’s revenue growth rate?
Cyclacel Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.